Immune checkpoint inhibitors (ICIs), such as pembrolizumab and nivolumab, which target programmed cell death protein 1 (PD-1), have become part of mainstream systemic treatments for RM-HNSCC [4]. This evidence concerns the gene PDCD1 and head and neck squamous cell carcinoma.